Cytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameCytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy
Drug Alias NameRadiation-sensitising gene therapy - NewGenPharm/Henry Ford Health SystemRadiation-sensitising gene therapyAd5-yCD/mutTKSR39rep-hIL12Ad5-CD/TKrepAd5-yCD/mutTKSR39rep-ADP +[7] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionCell death stimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic NeoplasmsBrain NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHenry Ford Health System
China Registration ClassN/A

Develop Information

Active CompaniesHenry Ford Health System
Inactive CompaniesNewgenpharm Inc
Active IndicationsBrain NeoplasmsGlioblastomaAstrocytoma +[4] 
Inactive IndicationsProstatic NeoplasmsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A